Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?Подробнее

What is the rationale behind the combination of glofitamab + polatuzumab in patients with R/R DLBCL?

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma.Подробнее

Polatuzumab Vedotin in PreviouslyUntreated Diffuse Large B-Cell Lymphoma.

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma

Safety and Efficacy of Mosunetuzumab Plus Polatuzumab VedotinПодробнее

Safety and Efficacy of Mosunetuzumab Plus Polatuzumab Vedotin

Glofitamab in R/R DLBCL: updated safety and efficacy dataПодробнее

Glofitamab in R/R DLBCL: updated safety and efficacy data

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCLПодробнее

COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in patients with high-risk DLBCL

Glofitamab and polatuzumab vedotin in DLBCLПодробнее

Glofitamab and polatuzumab vedotin in DLBCL

A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCLПодробнее

A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCL

SUNMO trial design: mosunetuzumab plus polatuzumab vedotin vs R-GemOx in R/R NHLПодробнее

SUNMO trial design: mosunetuzumab plus polatuzumab vedotin vs R-GemOx in R/R NHL

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCLПодробнее

Impact of TMTV on PFS following glofitamab treatment in R/R DLBCL

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCLПодробнее

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCL

A Phase I/II trial of glofitamab monotherapy in R/R MCLПодробнее

A Phase I/II trial of glofitamab monotherapy in R/R MCL

Dr. Hou on Polatuzumab Vedotin in DLBCLПодробнее

Dr. Hou on Polatuzumab Vedotin in DLBCL

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformationПодробнее

ASH highlights: glofitamab in DLBCL & pirtobrutinib and epcoritamab in Richter's transformation

Combination of mosunetuzumab with CHOP in DLBCLПодробнее

Combination of mosunetuzumab with CHOP in DLBCL

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FLПодробнее

Dr. Diefenbach on Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in FL

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCL